The history and future of targeting cyclin-dependent kinases in cancer therapy
Open accessThe DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Abstract
Cancer represents a pathological manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies. In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle. Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events. Translating this knowledge into successful clinical development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clinical trials. Here, we review the biology of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clinical results of CDK inhibitors. We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clinical activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Grade 3–4 neutropenia is observed in approximately 60% of patients taking palbociclib and ribociclib (Asghar et al., 2015; Hortobagyi et al., 2016).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Like palbociclib, these orally-bioavailable and highly selective CDK4/6-targeting agents exhibit IC50 values in the low nanomolar range, whereas other CDK family members are far less sensitive (1, 88, 89).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Such pan-CDK inhibitors had limited success, due in part to the dose limiting toxicities that hampered their use (Asghar et al., 2015).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“More than two decades after discovery of CDK4 and CDK6, drugs inhibiting their activities are now demonstrating significant efficacy in cancer treatment [for other recent reviews, see (1-3)].”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [1]
In the citing paper
“Abemaciclib appears to be better tolerated overall, with only 55% of patients experiencing significant adverse events (as compared to 70–80% with ribociclib and palbociclib) and only 21% with grade 3–4 neutropenia.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Asghar et al., 2015
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986
Cited by
Items 401–500 of 1,002
Androgen Receptor in Breast Cancer: From Bench to Bedside
Chen, M., Yang, Y., Xu, K., Li, L., Huang, J., & Qiu, F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00573 · Cited by 51
“CDK4 and CDK6, members of the CDK family, are activated by cyclin D and induce the transition from G1 phase to S phase in cell proliferation (87).”
BackgroundThreonine fuels glioblastoma through YRDC-mediated codon-biased translational reprogramming
Wu, X., Yuan, H., Wu, Q., Gao, Y., Duan, T., Yang, K., Huang, T., Wang, S., Yuan, F., Lee, D., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00748-7 · Cited by 50
“To rule out the possibility that the increased translation in GSCs is simply a byproduct of increased proliferation, we used a pan-cyclin-dependent kinase (CDK) inhibitor, alvocidib 18 , to reduce the proliferation of GSCs to a level comparable to that of paired DGCs (Extended Data Fig.”
Liu, X., Gao, Y., Shen, J. K., Yang, W., Choy, E., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0032 · Cited by 49
“org Mol Cancer Ther; 15(7) July 2016 1697”
BackgroundInfluentialThe awakening of the CDK10/Cyclin M protein kinase
Guen, V. J., Gamble, C., Lees, J. A., & Colas, P. (2017) · Oncotarget · doi:10.18632/oncotarget.15024 · Cited by 49
“A cornucopia of small-molecule inhibitors have been discovered and a subset evaluated in patients [3, 4].”
BackgroundBekker, G., Kamiya, N., Araki, M., Fukuda, I., Okuno, Y., & Nakamura, H. (2017) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.6b01127 · Cited by 49
Preusser, M., Mattos‐Arruda, L. D., Thill, M., Criscitiello, C., Bartsch, R., Ruhstaller, T., de Azambuja, E., & Zielinski, C. C. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000368 · Cited by 49
“Initial clinical experience with first-generation pan-CDK inhibitors has shown poor efficacy and important toxicity.(5) However, a new generation of highly selective CDK4/6 inhibitors including palbociclib, ribociclib and abemaciclib has overcome the challenges of non-specific pan-CDK inhibitors and targets tumour typ…”
BackgroundRiaz, A., Rasul, A., Kanwal, N., Hussain, G., Shah, M. A., Sarfraz, I., Ishfaq, R., Batool, R., Rukhsar, F., & Adem, Ş. (2020) · Current Drug Metabolism · doi:10.2174/1389200221999200728144801 · Cited by 49
Fouad, R., & Adly, O. M. I. (2020) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2020.129158 · Cited by 50
Riching, K. M., Schwinn, M. K., Vasta, J. D., Robers, M. B., Machleidt, T., Urh, M., & Daniels, D. L. (2021) · SLAS Discovery · doi:10.1177/2472555220973602 · Cited by 45
Cyclin-dependent Kinases as Emerging Targets for Developing Novel Antiviral Therapeutics
Gutiérrez-Chamorro, L., Felip, E., Ezeonwumelu, I. J., Vila, M. M., & Ballana, E. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.01.014 · Cited by 49
Wang, Y., Luo, R., Zhang, X., Xiang, H., Yang, B., Feng, J., Deng, M., Ran, P., Sujie, A., Zhang, F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36005-1 · Cited by 49
RetractedDevelopment of CDK4/6 Inhibitors: A Five Years Update
Ammazzalorso, A., Agamennone, M., Filippis, B. D., & Fantacuzzi, M. (2021) · Molecules · doi:10.3390/molecules26051488 · Cited by 50
“o ever, in recent years, the interest in identifying inhibitors of specific kinases ith targeted action on tu or cells and ith less toxic effects, has led to the discovery of selective CDK4/6 inhibitors [30,45].”
BackgroundStanciu, I.-M., Paroșanu, A. I., & Niţipir, C. (2023) · Biomolecules · doi:10.3390/biom13091422 · Cited by 48
“This CDK4 selectivity suggests that abemaciclib may significantly reduce the growth of breast cancer cells [53,54].”
BackgroundJane, E. P., Premkumar, D. R., Cavaleri, J., Sutera, P. A., Rajasekar, T., & Pollack, I. F. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.230052 · Cited by 48
“Dinaciclib inhibits CDKs 1, 2, 5, and 9 and entered phase 2 and 3 clinical trials in a range of malignancies and displayed tolerable toxicity (Parry et al., 2010; Nemunaitis et al., 2013; Fabre et al., 2014; Asghar et al., 2015, Kumar et al., 2015).”
BackgroundInfluentialLi, Y., Quan, J., Chen, F., Pan, X., Zhuang, C., Xiong, T., Zhuang, C., Li, J., Huang, X., Ye, J., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.102 · Cited by 48
Su, Y., Li, R., Ning, X., Lin, Z., Zhao, X., Zhou, J., Liu, J., Jin, Y., & Yin, Y. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.048 · Cited by 48
Hawash, M. (2019) · Drug Research · doi:10.1055/a-0898-7347 · Cited by 48
Yin, J., Zhang, H., Wu, X., Zhang, Y., Li, J., Shen, J., Zhao, Y., Xiao, Z., Lu, L., Huang, C.-L., et al. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4562 · Cited by 48
“It has been reported that heterodimeric complexes of CDK4/6 with cyclin D and CDK3 with cyclin C regulated cell‑cycle transition from G0 to G1 and early phases of G1 through the phosphorylation of retinoblastoma protein (18) while S and G2/M phase control were mediated by CDK2 and CDK1 (19).”
BackgroundSmall Molecule CDK Inhibitors for the Therapeutic Management of Cancer
Goel, B., Tripathi, N., Bhardwaj, N., & Jain, S. K. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200516152756 · Cited by 48
Zhang, P., Xu, B., Gui, L., Wang, W., Xiu, M., Zhang, X., Sun, G., Zhu, X., & Zou, J. (2021) · Biomarker Research · doi:10.1186/s40364-021-00271-2 · Cited by 48
“The myelosuppressive effects of dalpiciclib were considered an on-target effect due to the involvement of CDK6 in the proliferation of hematological precursors [25] and the cytostasis induced in G1 phase by dalpiciclib was reversible when the drug was held.”
BackgroundCDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy
Nardone, V., Barbarino, M., Angrisani, A., Correale, P., Pastina, P., Cappabianca, S., Reginelli, A., Mutti, L., Miracco, C., Giannicola, R., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168391 · Cited by 49
“Ribociclib is a selective strong inhibitor of CDK4 and CDK6 [13], blocks Rb phosphorylation, and causes cell cycle arrest of Rb-positive tumor cells, similarly to palbociclib [14].”
BackgroundTranscription associated cyclin-dependent kinases as therapeutic targets for prostate cancer
Constantin, T. A., Greenland, K. K., Varela‐Carver, A., & Bevan, C. L. (2022) · Oncogene · doi:10.1038/s41388-022-02347-1 · Cited by 48
“However, the promiscuity of these two inhibitors likely contributed to their failure in the clinic, following numerous patient toxicities and challenges in establishing an accurate pharmacodynamic profile in vivo [63].”
BackgroundMedical Management of Meningiomas
Karsy, M. J., Guan, J., Cohen, A. L., Colman, H., & Jensen, R. L. (2016) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2015.11.002 · Cited by 47
Cdk5 in Oncology: Recent Advances and Future Prospects
Lenjisa, J. L., Tadesse, S., Khair, N. Z., Kumarasiri, M., Yu, M., Albrecht, H., Milne, R. W., & Wang, S. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0097 · Cited by 47
Kong, T., Xue, Y., Cencic, R., Zhu, X., Monast, A., Fu, Z., Pilon, V., Sangwan, V., Guiot, M., Foulkes, W. D., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0162 · Cited by 48
“Three highly selective CDK4/6 inhibitors, palbociclib (PD-0332991), ribociclib (LEE001) and abemaciclib (LY2835219), are FDA-approved for treating estrogen receptor-positive (ER + ) advanced breast cancers, which are often characterized by dysregulated CDK4/6 activation (1-3).”
BackgroundResultOudaha, K. H., Najm, M. A. A., Samir, N., Serya, R. A. T., & Abouzid, K. A. M. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103239 · Cited by 47
“It is winding up obvious that many sorts of tumors are the consequence of irregular signal-transducing proteins that prompt a persistent generation of the signal for cell division [1].”
BackgroundInfluentialα‑Solanine inhibits growth and metastatic potential of human colorectal cancer cells
Xia, Y., Li, M., Chen, L., Xiao, P., Que, Z., An, H., Shen, K., & Hu, B. (2020) · Oncology Reports · doi:10.3892/or.2020.7519 · Cited by 47
“, cyclin E and CDK2, and also promotes cell cycle progression from the G1 to the S phase (23).”
BackgroundXi, J., & Ma, C. X. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00917-8 · Cited by 47
Synergistic drug combinations and machine learning for drug repurposing in chordoma
Anderson, E. N., Havener, T. M., Zorn, K. M., Foil, D. H., Lane, T. R., Capuzzi, S. J., Morris, D., Hickey, A. J., Drewry, D. H., & Ekins, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-70026-w · Cited by 47
Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors
Gomatou, G., Trontzas, I. P., Ioannou, S., Drizou, M., Syrigos, N. K., & Kotteas, E. A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-020-06100-3 · Cited by 47
Gonzalez-Valero, A., Reeves, A. G., Page, A. C. S., Moon, P. J., Miller, E., Coulonval, K., Crossley, S. W. M., Xie, X., He, D., Musacchio, P. Z., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c04039 · Cited by 48
Soldera, S. V., & Leighl, N. B. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00050 · Cited by 47
Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer
Rao, S. S., Stoehr, J. R., Đokić, D., Wan, L., Decker, J. T., Konopka, K. E., Thomas, A. L., Wu, J., Kaklamani, V., Shea, L. D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20202 · Cited by 48
“Previously, flavopiridol, an inhibitor of CDKs 1, 2, 4, 6, 7, and 9, was shown to induce both cancer cell cycle arrest and cytotoxic effects [27].”
InfluentialCyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 – 2014)
Malínková, V., Vylíčil, J., & Kryštof, V. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1045414 · Cited by 46
“Potent monospecific CDK7 and CDK9 inhibitors have been disclosed.”
BackgroundInfluentialThe Essential Transcriptional Function of BRD4 in Acute Myeloid Leukemia
Roe, J., & Vakoc, C. R. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.031039 · Cited by 46
Cheng, R., Liu, Y.-J., Cui, J., Yang, M., Liu, X., Li, P., Wang, Z., Zhu, L., Lu, S., Zou, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16325 · Cited by 46
“Drugs that target this axis can be used in the treatment of cancers especially breast cancer [17, 18, 44, 45].”
BackgroundPuli, O. R., Danysh, B. P., McBeath, E., Sinha, D. K., Hoang, N. M., Powell, R. T., Danysh, H. E., Cabanillas, M. E., Cote, G. J., & Hofmann, M.-C. C. (2018) · Neoplasia · doi:10.1016/j.neo.2018.09.003 · Cited by 46
“[71] Asghar U,Witkiewicz AK, Turner NC, and Knudsen ES (2015).”
BackgroundIdentification of Targetable Lesions in Anaplastic Thyroid Cancer by Genome Profiling
Ravi, N., Yang, M., Gretarsson, S., Jansson, C., Mylona, N., Sydow, S., Woodward, E. L., Ekblad, L., Wennerberg, J., & Paulsson, K. M. (2019) · Cancers · doi:10.3390/cancers11030402 · Cited by 46
“Although there are no drugs that are available that specifically targets CCNE1, multiple inhibitors for CDKs are under development and could be viable treatment options in CCNE1- and CDK6-amplified ATC [29,35].”
BackgroundLord, C. J., Quinn, N., & Ryan, C. J. (2020) · eLife · doi:10.7554/elife.58925 · Cited by 47
“9 its negative regulators CDK4 and CDK6, consistent both with the known Rb pathway structure and with preclinical data suggesting that RB1 mutation confers resistance to CDK4/6 inhibitors(Asghar et al., 2015; O’Leary et al., 2018).”
BackgroundEl‐Sayed, A. A., Nossier, E. S., Almehizia, A. A., & Amr, A. E. E. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.131285 · Cited by 46
Cui, X., Peng, Q., Li, R., Lyu, X., Zhu, C., & Qin, X. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17032 · Cited by 46
Amani, J., Gorjizadeh, N., Younesi, S., Najafi, M., Ashrafi, A. M., Irian, S., Gorjizadeh, N., & Azizian, K. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103103 · Cited by 45
Taghizadeh, M. S., Taherishirazi, M., Niazi, A., Afsharifar, A., & Moghadam, A. A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1327820 · Cited by 45
“This limits their potential as therapeutic agents or chemical probes (Asghar et al., 2015).”
BackgroundThomas, A. L., Lind, H., Hong, A., Đokić, D., Oppat, K. M., Rosenthal, E., Guo, A., Thomas, A. J., Hamden, R., & Jeruss, J. S. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1338988 · Cited by 45
“This may have been due to lack of target specificity or absence of patient selection based on clinically relevant biomarkers.(11) With the recent development of CDK inhibitors with higher specificity, clinical successes have been identified.”
BackgroundQiao, L., Liu, X., Tang, Y., Zhao, Z., Zhang, J., & Feng, Y. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.08.024 · Cited by 45
Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy
Robb, C. M., Kour, S., Contreras, J. I., Agarwal, E., Barger, C. J., Rana, S., Sonawane, Y. A., Neilsen, B. K., Taylor, M., Kizhake, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23749 · Cited by 45
“While they showed promise in targeting CDKs, they often required high doses which resulted in off-target effects and significant toxicity in preclinical animal trials [17].”
BackgroundCheng, Z.-J., Miao, D.-L., Su, Q.-Y., Tang, X.-L., Wang, X.-L., Deng, L.-B., Shi, H., & Xin, H. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0187-3 · Cited by 45
Anwer, M. K., Fatima, F., Ahmed, M. M., Aldawsari, M. F., Alali, A. S., Kalam, M. A., Alshamsan, A., Alkholief, M. A., Malik, A., Alanazi, A. Z., et al. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.03.019 · Cited by 45
Xie, S. P., Jiang, H., Zhai, X., Fan, W. Q., Wang, S., Ding, J., & Chen, Y. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.49 · Cited by 45
Identification of Ten Core Hub Genes as Potential Biomarkers and Treatment Target for Hepatoblastoma
Sun, R., Li, S., Zhao, K., Diao, M., & Li, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.591507 · Cited by 44
Ziegler, Y., Guillen, V. S., Kim, S. H., Katzenellenbogen, J. A., & Katzenellenbogen, B. S. (2021) · Cancers · doi:10.3390/cancers13246282 · Cited by 44
Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors
Hussain, S., Mursal, M., Verma, G., Hasan, S. S., & Khan, M. F. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176484 · Cited by 44
Mirza, M. R., Bjørge, L., Marmé, F., Christensen, R. D., Gil-Martín, M., Auranen, A., Ataseven, B., Rubio, M. J., Salutari, V., Luczak, A. A., et al. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.12.003 · Cited by 44
Jayaraman, S., Eswaran, A., Rajagopal, P., Palanisamy, C. P., Veerakumar, P., Veeraraghavan, V. P., & Sirasanagandla, S. R. (2026) · Biogerontology · doi:10.1007/s10522-026-10402-7 · Cited by 44
“Moreover, the cell cycle can be stopped and senescence triggered by CDK inhibitors such as Palbociclib (CDK4/6), PF-06873600 (CDK2/4/6), and CDK7/12 inhibitors (e.g., SY-5609, CDK12-IN-3) (Asghar et al. 2015; Kwiatkowski et al. 2014).”
The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer
Alexandrou, S., George, S. M., Ormandy, C. J., Lim, E., Oakes, S. R., & Caldon, C. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030667 · Cited by 44
“Pa nC D K in hi bi to r Dinaciclib [99,118,119] (MK7965, SCH727965; Merck & Co.”
BackgroundStarrett, G. J., Serebrenik, A. A., Roelofs, P. A., Verhalen, B., McCann, J. L., Jarvis, M. C., Stewart, T. A., Law, E. K., Krupp, A., Jiang, M., et al. (2019) · mBio · doi:10.1128/mbio.02690-18 · Cited by 44
Mitotic Poisons in Research and Medicine
Škubník, J., Jurášek, M., Ruml, T., & Rimpelová, S. (2020) · Molecules · doi:10.3390/molecules25204632 · Cited by 44
Super-enhancer in prostate cancer: transcriptional disorders and therapeutic targets
Chen, X., Ma, Q., Shang, Z., & Niu, Y. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-00137-0 · Cited by 45
CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer
Saleh, L., Wilson, C., & Holen, I. (2021) · MedComm · doi:10.1002/mco2.97 · Cited by 44
Peuker, C. A., Yaghobramzi, S., Grunert, C., Keilholz, L., Gjerga, E., Hennig, S., Schaper, S., Na, I., Keller, U. B., Brucker, S. Y., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.025 · Cited by 44
Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies
Rosario, R., Cui, W., & Anderson, R. A. (2022) · Reproduction and Fertility · doi:10.1530/raf-22-0020 · Cited by 44
Masurkar, P. P., Damgacioglu, H., Deshmukh, A. A., & Trivedi, M. V. (2023) · PharmacoEconomics · doi:10.1007/s40273-023-01245-y · Cited by 44
Costa, R. L. B., Carneiro, B. A., Wainwright, D. A., Santa-Maria, C. A., Kumthekar, P., Chae, Y. K., Gradishar, W. J., Cristofanilli, M., & Giles, F. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw532 · Cited by 44
Therapeutic Approaches for Zika Virus Infection of the Nervous System
Abrams, R. P. M., Solis, J., & Nath, A. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0575-2 · Cited by 44
Oncogenic action of the exosome cofactor RBM7 by stabilization of CDK1 mRNA in breast cancer
Xi, P.-W., Zhang, X., Zhu, L., Dai, X., Cheng, L., Hu, Y., Shi, L., Wei, J., & Ding, Q. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-00200-w · Cited by 43
Skp2: A critical molecule for ubiquitination and its role in cancer
Feng, T., Wang, P., & Zhang, X. (2024) · Life Sciences · doi:10.1016/j.lfs.2023.122409 · Cited by 43
Applications of protein ubiquitylation and deubiquitylation in drug discovery
Chen, Y., Xue, H., & Jin, J. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107264 · Cited by 43
Targeting CDK2 for cancer therapy
Knudsen, E. S., Witkiewicz, A. K., Sanidas, I., & Rubin, S. M. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116140 · Cited by 43
Self-citationPalbociclib has antitumour effects on Pten‐deficient endometrial neoplasias
Santamaría, M. D., Mirantes, C., Eritja, N., Felip, I., Navaridas, R., Gatius, S., Santacana, M., Colás, E., Moiola, C. P., Schoenenberger-Arnaiz, J. A., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4896 · Cited by 43
“Therapeutic intervention in the cell cycle has been proposed as an effective antitumour therapy [38,39].”
BackgroundWang, Y.-T., Pan, S., Tsai, C.-F., Kuo, T.-C., Hsu, Y.-L., Yen, H., Choong, W.-K., Wu, H.-Y., Liao, Y., Hong, T.-M., et al. (2017) · Scientific Reports · doi:10.1038/srep44021 · Cited by 43
Chen, M., Wu, R., Li, G., Liu, C., Tan, L., Xiao, K., Ye, Y., & Qin, Z. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0829-9 · Cited by 43
Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs
Green, J. L., Okerberg, E. S., Sejd, J. R., Palafox, M., Monserrat, L., Alemayehu, S., Wu, J., Sykes, M., Aban, A., Serra, V., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0755 · Cited by 43
CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets
Kohlmeyer, J. L., Gordon, D. J., Tanas, M. R., Monga, V., Dodd, R. D., & Quelle, D. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21083018 · Cited by 43
“While many of these inhibitors displayed less severe toxicities, their anti-cancer activities in early phase clinical trials were highly variable between different tumor types [183,184].”
BackgroundTSPAN7 Exerts Anti-Tumor Effects in Bladder Cancer Through the PTEN/PI3K/AKT Pathway
Yu, X., Li, S., Pang, M., Du, Y., Xu, T., Bai, T., Yang, K., Hu, J., Zhu, S., Wang, L., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.613869 · Cited by 43
“org 10 be found in various solid tumors and is closely related to the development of tumors (36).”
BackgroundBiology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation
Motofei, I. G. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.10.003 · Cited by 43
Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma
Ishio, T., Kumar, S., Shimono, J., Daenthanasanmak, A., Dubois, S. P., Lin, Y., Bryant, B. R., Petrus, M. N., Bachy, E., Huang, D. W., et al. (2021) · Blood · doi:10.1182/blood.2021012734 · Cited by 43
The Regulation of Cyclins and Cyclin-Dependent Kinases in the Development of Gastric Cancer
Javed, A., Yarmohammadi, M., Korkmaz, K., & Rubio‐Tomás, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032848 · Cited by 43
Wang, Y., Chen, Y., Cheng, X.-L., Zhang, K., Wang, H., Liu, B., & Wang, J. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.05.024 · Cited by 43
Li, A., Fan, S., Xu, Y., Meng, J., Shen, X., Mao, J., Zhang, L., Zhang, X., Moeckel, G., Wu, D., et al. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13091 · Cited by 42
“Most cyclins couple with CDKs to form CDK/cyclin complexes which control kinase activity and substrate specificity [66, 67].”
BackgroundHelsten, T. L., Kato, S., Schwaederle, M. C., Tomson, B. N., Buys, T. P. H., Elkin, S. K., Carter, J. L., & Kurzrock, R. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0071 · Cited by 42
“Upregulation of CDK4/6 may occur via CDK4 or CDK6 amplification, inactivation of CDKN2A/B, or CCND1 amplification, which subsequently augments phosphorylation and inactivation of RB1 (4, 5).”
BackgroundAn essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia
Lopez, S., Voisset, E., Tisserand, J. C., Mosca, C., Prébet, T., Santamaría, D., Dubreuil, P. C., & Sepulveda, P. D. (2016) · Oncotarget · doi:10.18632/oncotarget.9965 · Cited by 42
“Thus, CDK4/6 activity appears as a promising therapeutic target for cancer treatment [20].”
A CDK2 activity signature predicts outcome in CDK2-low cancers
McCurdy, S. R., Pacal, M., Ahmad, M. A. E.-R., & Bremner, R. (2016) · Oncogene · doi:10.1038/onc.2016.409 · Cited by 43
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment
Parylo, S., Vennepureddy, A., Dhar, V., Patibandla, P., & Sokoloff, A. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218770904 · Cited by 42
TNNT1 facilitates proliferation of breast cancer cells by promoting G1/S phase transition
Shi, Y., Zhao, Y., Zhang, Y., AiErken, N., Shao, N., Ye, R., Lin, Y., & Wang, S. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.07.034 · Cited by 42
Sun, J., Du, Y., Song, Q., Jing, N., Guan, P., Guo, J., Wang, X., Yang, J., & Zhao, C. (2019) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmy174 · Cited by 42
Somarelli, J. A., Roghani, R. S., Moghaddam, A. S., Thomas, B. C., Rupprecht, G., Ware, K. E., Altunel, E., Mantyh, J. B., Kim, S. Y., McCall, S. J., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0454 · Cited by 42
Janoštiak, R., Torres-Sanchez, A., Posas, F., & de Nadal, E. (2022) · Cancers · doi:10.3390/cancers14051265 · Cited by 42
He, J., Jin, Y., Zhou, M., Li, X., Chen, W., Wang, Y., Gu, S., Cao, Y., Chu, C., Liu, X., et al. (2017) · Cancer Science · doi:10.1111/cas.13478 · Cited by 41
“Numerous CDK inhibitors were expected to be an effective strategy because many tumorigenic events eventually drive proliferation by subverting CDK4 or CDK6 complexes in the G1 phase of the cell cycle.(29,30) Therefore, clarifying the mechanism concerning the dysregulation of cell cycle regulator will be of great impor…”
BackgroundIgarashi, K., Kawaguchi, K., Kiyuna, T., Miyake, K., Miyaki, M., Yamamoto, N., Hayashi, K., Kimura, H., Miwa, S., Higuchi, T., et al. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.10.119 · Cited by 43
P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib
Li, P., Zhang, X., Gu, L., Zhou, J., & Deng, D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223084 · Cited by 42
Ito, H., Watari, K., Shibata, T., Miyamoto, T., Murakami, Y., Nakahara, Y., Izumi, H., Wakimoto, H., Kuwano, M., Abé, T., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0438 · Cited by 41
Grizzi, G., Ghidini, M., Botticelli, A., Tomasello, G., Ghidini, A., Grossi, F., Fusco, N., Cabiddu, M., Savio, T., & Petrelli, F. (2020) · Cancer Management and Research · doi:10.2147/cmar.s202965 · Cited by 41
“ER+ Advanced BC Clinical Data of CDK 4/6 Inhibitors in Advanced ER+ BC The first generation of CDK 4/6 inhibitors revealed futility due to the toxicity and selectivity of drugs.(29) Next-generation CDK inhibitors were developed with greater selectivity towards isoforms 4 and 6, resulting in more effective and less tox…”
BackgroundEldehna, W. M., Maklad, R. M., Almahli, H., Al-Warhi, T. I., Elkaeed, E. B., Abourehab, M. A. S., Abdel‐Aziz, H. A., & Kerdawy, A. M. E. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2062337 · Cited by 41
Anti-tumor pharmacology of natural products targeting mitosis
Huang, M., Liu, C., Shao, Y., Zhou, S., Hu, G., Yin, S., Pu, W., & Yu, H. (2022) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0006 · Cited by 41
Cyclin-dependent kinase inhibitors in malignant hematopoiesis
Schirripa, A., Sexl, V., & Kollmann, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.916682 · Cited by 41
Hylsová, M., Carbain, B., Fanfrlík, J., Musilová, L., Haldar, S., Köprülüoğlu, C., Ajani, H., Brahmkshatriya, P. S., Jorda, R., Kryštof, V., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.023 · Cited by 40
MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma
Bustos, M. A., Ono, S., Marzese, D. M., Oyama, T., Iida, Y., Cheung, G., Nelson, N. E., Hsu, S. C., Yu, Q., & Hoon, D. S. �. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.03.039 · Cited by 41
“The functional and clinical relevanceof the pathway in different cancers has fueled the development of improved selective CDK inhibitor compounds, including PD-0332991 (palbociclib) (Asghar et al., 2015; Roskoski, 2016; Xu et al., 2016).”
BackgroundZhang, C., Stockwell, S. R., Elbanna, M., Ketteler, R., Freeman, J., Al‐Lazikani, B., Eccles, S. A., Brandon, A. D. H., Raynaud, F. I., Hayes, A., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0850-2 · Cited by 40
“Activation of CDK4/6 requires their binding to D-type cyclins, synthesised in response to mitogenic signals [12, 13].”
BackgroundShi, J., Lv, S., Wu, M., Wang, X., Deng, Y., Li, Y., Li, K., Zhao, H., Zhu, X., & Ye, M. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.21 · Cited by 40
“CDK4/CDK6 inhibitor palbociclib reduces tumor growth by reducing retinoblastoma (RB) protein phosphorylation and cell cycle arrest, which induces G1/S phase transition.(11) In recent years, CDK4/CDK6 inhibitors have become a powerful drug for the treatment of cancer.”
BackgroundGetting under the skin: The role of CDK4/6 in melanomas
Guo, L., Qi, J., Wang, H., Jiang, X. L., & Liu, Y. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112531 · Cited by 40
Metadata
- Authors
- Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S.
- Affiliations
- Institute of Cancer Research (GB)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Royal Marsden NHS Foundation Trust (GB)
- Corresponding author
- Knudsen, Erik S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-01-30
- Volume
- 14
- Issue
- 2
- Pages
- 130-146
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC4480421
- OpenAlex
- W2057272791
- Cited by
- 1,767
- References
- 210
- Citations by year
- 2026: 100 · 2025: 157 · 2024: 157 · 2023: 170 · 2022: 180 · 2021: 200 · 2020: 185 · 2019: 148 · 2018: 150 · 2017: 161 · 2016: 112 · 2015: 46
- FWCI
- 27.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Consortium canadien en neurodégénérescence associée au vieillissement
- Cancer Research UK (16642)
- National Cancer Institute (R01CA129134, CA129134, CA188650, R01CA188650, CA163863, R01CA163863)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- cyclin-dependent kinases, cyclin-dependent kinase inhibitors, CDK4, CDK6, CDK2, CDK1, cell cycle regulation, G1 phase, chromosome stability, S phase, anticancer drug development, clinical trials, patient stratification, kinase selectivity
- MeSH terms
- Animals, Antineoplastic Agents, Cell Cycle, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Neoplasms, Molecular Structure, Signal Transduction, Gene Expression Regulation, Neoplastic, Cyclin-Dependent Kinases, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.